Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

Inclusion Criteria:

• Hospitalized patients with acute myocardial infarction according to Cardiac biomarker values [Selective cardiac troponin (cTc) elevation and/or decline detection, at least one value exceeds the 99% reference limit (URL) and at least one of the following:（1）Symptoms of myocardial ischemia；（2）New or suspected new obvious ST-T changes or new left bundle branch block (LBBB)；（3）ECG pathological Q waves；（4）Image evidence of recent loss of viable myocardium, or new regional wall motion abnormalities；（5）Coronary thrombosis confirmed by angiography or autopsy.]

Exclusion Criteria:

• Those who did not meet the diagnosis of acute myocardial infarction (no myocardial ischemia-related symptoms, elevation of markers of myocardial necrosis and imaging findings of myocardial infarction); those who met the inclusion criteria but refused to participate in the study; The researchers judged that the subjects had poor compliance and could not Complete follow-up as required.

Hospitalized patients with acute myocardial infarction from 36 hospitals in Tianjin were enrolled between January 2015 and January 2020